此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Peds Proton Therapy

2026年11月13日 更新者:University of Wisconsin, Madison

Operational and Clinical Evaluation of the Treatment Planning Software and Oncology Information System for Pediatric Proton Therapy

This study is being done to evaluate the clinical utilization and safety of RayStation 2025 and RayCare 2025 treatment planning software upgrades when used to support standard-of-care proton therapy delivery in patients deemed clinically appropriate for such therapy by their treating radiation oncologist.

研究概览

详细说明

In this study, the radiation treatment itself, including target definitions, prescription dose, treatment delivery, verification imaging, and adaptive treatment planning, is standard of care.

Current standard radiation therapy planning is based on a treatment plan generated from a planning computed tomography (CT) scan obtained before treatment begins. This plan is generally used for the entire course of therapy, with verification imaging performed during treatment primarily used to verify patient positioning rather than to recalculate delivered dose. On occasion, it is standard practice for a physician to determine, based on his or her interpretation of verification imaging, that an adaptive replanning of the treatment is needed to account for anatomic changes that the physician observes on verification imaging which mandate a change to the plan. Comprehensive software-based evaluation of the cumulative dose delivered over multiple fractions is not routinely performed in most clinical settings. Performing such evaluations typically requires manual steps including image registration, dose recalculation on additional imaging datasets, deformable dose mapping, and manual accumulation of dose across fractions. With currently FDA-approved tools for proton therapy treatment plan evaluation, these processes are time-consuming and require significant physics and physician resources. As a result, detailed adaptive dose evaluation is usually performed only in selected cases or as a one-time assessment during a treatment course, rather than as a routine component of daily clinical care.

The investigational component involves the prospective evaluation of the RayAdaptive and RayTracker software tools to assess their performance, reliability, usability, and clinical feasibility. These software features are not currently available for routine clinical use, being not yet FDA-cleared, in the configuration evaluated in this protocol and are being assessed in a defined prospective clinical research setting.

This is a nonrandomized, single arm, open-label, prospective interventional trial to determine the rate of adaptive replanning for proton therapy when RayTracker and RayAdaptive are used as decision-support tools in the analysis of every verification image obtained during each participant's proton therapy treatment course. This study will evaluate, under a defined prospective clinical research framework, the performance, reliability, usability, and clinical feasibility of implementing RayTracker and RayAdaptive - software components that have not yet been 510(k) cleared by the U.S. Food and Drug Administration (FDA).

Primary Objective

• To determine the frequency of adaptive replanning during proton therapy when RayTracker and RayAdaptive are incorporated into routine verification image review as clinical decision-support tools.

Secondary Objectives

  • To evaluate the treating physician-reported rate at which RayTracker and RayAdaptive influenced the decision to pursue adaptive replanning during proton therapy.
  • To explore concordance between RayAdaptive-predicted inadequate target coverage on verification imaging and findings on repeat CT simulation when performed.
  • To explore concordance between RayAdaptive-predicted organ-at-risk dose constraint violations and findings on repeat CT simulation when performed.
  • To report the incidence of adverse events (AEs) and device deficiencies related to the investigational RayTracker/RayAdaptive software.

研究类型

介入性

注册 (估计的)

80

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Wisconsin
      • Madison、Wisconsin、美国、53792
        • 招聘中
        • University of Wisconsin

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

不超过 17年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age less than or equal to 17 years at the time of consent/assent.
  • Patient has a clinical indication for radiation therapy, and the treating radiation oncologist has independently determined that proton therapy is clinically appropriate and has recommended proton therapy as part of the patient's routine clinical care, independent of participation in this research study. Proton therapy may be delivered with or without anesthesia when clinically indicated.
  • Written informed consent will be obtained from adult subjects or the parent/legal guardian of pediatric subjects. Assent will be obtained from pediatric participants when appropriate according to institutional policy.

Exclusion Criteria:

  • Patient has contraindications to proton therapy (per standard clinical guidelines).
  • Patient is unable to comply with routine treatment workflow or follow-up.
  • Patients who will be treated with a radiation plan of 5 fractions or fewer.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Standard of Care Proton Therapy

Part of a not yet FDA-cleared software, the RaySearch treatment planning system and RayCare oncology information system. RayTracker enables longitudinal evaluation of treatment by recalculating dose on daily images and accumulating dose across fractions using deformable image registration, thereby providing an estimate of the cumulative delivered dose to targets and organs at risk. RayAdaptive uses daily treatment imaging (such as cone-beam CT (CBCT)) together with the planning CT to generate an updated representation of patient anatomy and recalculation of dose on the current patient anatomy, allowing clinicians to evaluate whether anatomical changes could meaningfully alter the planned dose distribution. These features are designed to be used in tandem. Their combined capabilities are intended to support clinical decision-making related to treatment monitoring and potential adaptation.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Proportion of verification image assessments for each subject resulting in a clinical adaptive replanning decision
大体时间:up to 6 months

Defined as ordering repeat CT simulation and/or treatment plan reoptimization.

up to 6 months

次要结果测量

结果测量
措施说明
大体时间
Treating physician-reported influence of RayTracker/RayAdaptive on adaptive replanning decisions
大体时间:up to 6 months

Can I define this outcome to be: Did the RayTracker / RayAdaptive intervention influence your clinical decision? [Yes / No] This will be reported by physician count.

up to 6 months
Concordance between RayAdaptive predictions of inadequate target coverage and findings on repeat CT simulation
大体时间:up to 6 months
up to 6 months
Concordance between RayAdaptive predictions of organ-at-risk dose constraint violations and findings on repeat CT simulation
大体时间:up to 6 months
up to 6 months
Incidence of AEs and device deficiencies
大体时间:up to 6 months

Incidence of AEs and device deficiencies at least possibly related to use of the investigational RayTracker/RayAdaptive software or its incorporation into the clinical workflow as assessed throughout the course of proton therapy and for 90 days following completion of proton treatment. Device deficiencies may include software malfunction, calculation error, deformable registration failure, software defect, or software limitations affecting treatment plan evaluation, image review, or data analysis.

up to 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Brett Morris, MD, PhD、UW School of Medicine and Public Health

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月13日

初级完成 (估计的)

2029年1月1日

研究完成 (估计的)

2029年1月1日

研究注册日期

首次提交

2026年11月13日

首先提交符合 QC 标准的

2026年11月13日

首次发布 (实际的)

2026年11月19日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2026-1312
  • Protocol Version 7/26/26 (其他标识符:UW Madison)
  • SMPH | Radiation Medicine (其他标识符:UW Madison)
  • UW26111 (其他标识符:OnCore ID)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅